NY-CIRIUM
23.8.2022 14:02:54 CEST | Business Wire | Press release
Cirium, the aviation analytics firm, has announced that former Spirit Airlines CEO, Ben Baldanza and former Indigo CCO, Willy Boulter have joined the Cirium On-Time Performance (OTP) Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005442/en/
Cirium is the first and only company that has an OTP Advisory Board in the aviation industry. The Board comprises a collaborative team of external advisors who support Cirium’s OTP Program and reports global Annual and Monthly airline and airport on-time analyses.
“We are delighted to welcome Ben and Willy to the Cirium OTP Advisory Board. Together they bring nearly 80 years of aviation experience to the Board, which will be invaluable for Cirium’s airline and airport OTP Program. They will provide key focus and direction on the big-picture initiatives,” said Jeremy Bowen , CEO at Cirium.
Ben Baldanza is a transformational leader in the US airline industry. He was president and CEO for Spirit Airlines and changed that airline into an ultra-low-cost-airline carrier. Prior to Spirit he held executive roles with US Airways, Continental Airlines and TACA Airlines.
In addition to the Cirium OTP Board, Baldanza currently serves on the Board of Directors for JetBlue Airways, Six Flags Entertainment and several private companies. He also co-hosts a weekly podcast that is now in the top 1% of all podcasts by weekly listeners. Baldanza has also been twice named as one of the industry’s 25 Most Influential Leaders .
Baldanza said: “Airline and airport operational performance is increasingly important as the industry recovers from the pandemic and contends with rising challenges such as forecasting travel demand. Cirium’s OTP Program measures the carriers’ and airports’ operational efficiencies and is the standard for on-time arrival and departure benchmarking.”
Willy Boulter has 40 years’ experience in the airline industry, most recently as CCO at India’s largest airline IndiGo. Prior to IndiGo, Boulter was CCO in the Emirates-sponsored team that turned around TAAG Angola Airlines. He held executive roles at Gulf Air, Etihad Airways, low-cost carrier Sky Express, Virgin Atlantic and Cathay Pacific. Boulter also served in the British Army in the UK, Canada and Hong Kong and is a fellow of the Royal Aeronautical Society.
Boulter said: “It’s a privilege to join the Cirium OTP Advisory Board to help steer an accurate analysis of airline and airport operations. The program has multiple benefits for the industry, not least enabling improved operational performance and tracking aircraft utilization aligned to sustainability targets.”
Baldanza and Boulter join Luis Felipe de Oliveira , Director General at ACI World and Henry H. Harteveldt, President – Travel Industry Analyst at Atmosphere Research Group on the Board.
Click here to download the latest Cirium On-Time Performance Monthly Report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005442/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom